Learn more about investing using our online tools and research and invest in Rands and. The merger agreement has been approved by the Board of Directors of each company. EasyEquities is South Africas best low-cost investment platform. Upon closing of the merger, TYME will become a wholly owned subsidiary of Syros. In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME's expected net cash at closing and TYME stockholders are expected to receive approximately 0.4312 shares of Syros common stock for each share of TYME common stock. New and existing investors in the PIPE were led by a life sciences-focused investment fund.įollowing the closing of the merger, financing and debt agreement amendment, the total cash balance of the combined company is expected to be approximately $240 million (after transaction expenses), sufficient to fund Syros' planned operating expenses and capital expenditure requirements into 2025. Each outstanding and unexercised warrant to purchase shares of Tyme common stock, other than the warrants issued by the Company on May 20, 2020, were also assumed by Syros and converted into a warrant to purchase shares of Syros common stock, with necessary adjustments to reflect the exchange ratio. Our lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and we are preparing to initiate an additional Phase II clinical trial for pancreatic cancer.Concurrent with the merger, Syros announced an oversubscribed $130 million private investment in public equity (PIPE) financing at a price per unit of $0.94. Unlike targeted therapies that attempt to regulate specific mutations within cancer, our therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. We believe that listing on NASDAQ will help broaden and diversify our shareholder base, provide better liquidity and ultimately contribute to our ability to increase shareholder value.†About Tyme Other terms include any time money, cashline, tyme machine. Steve Hoffman, Co-Founder, Chief Executive and Chief Science Officer, stated, “Our listing on NASDAQ is a major corporate milestone for Tyme, and I’m extremely pleased with the significant progress we have made over the past few years with advancing the clinical development of our lead oncology candidate SM-88. own CVV credit Find Unicredit Bankomat stock photos and editorial news pictures from. tyme Joey Falcone Strategy: Joined 1/2020 0 Following 0 Followers 2 Posts 269 Liked 8 Watchlist Portfolio, a newsletter by Stocktwits. ( Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced financial and operating results for its fourth fiscal quarter and full year ended March 31, 2022. Compare Todays Range 0.29 0.32 50-Day Range 0. Not an offer or recommendation by Stocktwits. BEDMINSTER, N.J., (GLOBE NEWSWIRE) TYME Technologies, Inc. Tyme Technologies (TYME) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Trading on the NASDAQ Capital Market is expected commence on July 31, 2017, and the Company’s shares of common stock will begin trading on such date under a new ticker symbol “TYME.†Joey Falcone (tyme) Stocktwits 3rd Party Ad. (OTCQB:TYMI), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced that its shares of common stock were approved for listing on the NASDAQ Capital Market. NEW YORK, J(GLOBE NEWSWIRE) - Tyme Technologies, Inc.
0 Comments
Leave a Reply. |